Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with (R)-GemOx in Relapsed/Refractory Aggressive NHL
NCT03366272Phase 3Completed
- Sponsor
- Saarland University
- Start
- Dec 2017
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of nivolumab in non-Hodgkin lymphoma (NHL), sponsored by Saarland University. Started Dec 2017; status: completed.
02
Drugs
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03366272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03366272.